1. (valid email required)
 

cforms contact form by delicious:days

CRi Biomedical Imaging Systems Used by World’s Top Pharmaceutical Companies

February 23, 2010

Biotechnology Leader Provides Technology of Choice for Leading Pharmaceutical Industry Scientists

Woburn, Massachusetts – January 27, 2010

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, announced that 18 out of the top 20 pharmaceutical companies worldwide are using CRi’s optical imaging systems. These top pharmaceutical companies, ranked by revenue by Med Ad News in September 2009, have chosen CRi systems for molecular-based drug development and research.

There is a growing consensus among scientists that fulfilling the promise of molecular medicine requires a shift from the study of single events to viewing complex biological systems in their entirety. CRi’s integrated imaging products provide researchers and clinicians with quantitative assessments of disease and drug response. This is accomplished by evaluating multiple markers simultaneously in intact tissue samples, at a cellular level or in living small animals. CRi’s solutions have received strong industry recognition for having a significant impact in translational and clinical research and applications.

“The acceptance of CRi solutions by the world’s leading pharmaceutical companies further establishes the trend for drug development efforts, particularly in areas such as oncology, to focus on developing targeted therapies for more molecularly defined patient populations,” said George Abe, chief executive officer at CRi. “Researchers realize the significant capabilities of CRi’s platform technology and the efficiency and productivity gains that they provide, along with the potential to translate into diagnostic applications.”

CRi’s diverse and applications-focused products have revolutionized fluorescence and brightfield microscopy, in vivo imaging and assisted reproductive technologies. Based on its proprietary technology, CRi systems enable researchers to better explore biological pathways in drug development and personalized medicine by bridging the gap between combinatorial chemistry, flow cytometry and morphological imaging.

About CRi

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin, 781-935-9099

Marketing Manager

cboutin@cri-inc.com

or

Commonwealth Creative Associates

Jamie Bull, 508-620-0791

Digital Media Strategist

jamieb@commcreative.com

or

Commonwealth Creative Associates

Donna Phelps, 508-620-0791

Senior Account Executive

donnap@commcreative.com

Latest News

AspenTech Releases Version 8.5 of aspenONE® Manufacturing and Supply Chain Software

Quadrant Software Announces Acquisition of BCD and ExcelSystems Software Development

8 Cardio Machines That Really Work

Holyoke Company Adds Some Glitz to the Super Bowl

HighRoads Launches Medicare Advantage Governance Solution for Health Insurance Payers

Advanced Practice Strategies Announces New Chief Executive Officer

Curaspan Health Group Announces the Release of OutreachCentral to Automate Post-Discharge Communication for Patients at High Risk of Readmission

Payers Getting Health Care Exchange Ready with HighRoads SaaS Solution Enabling Accurate, Concise Plan Details


Latest Newsletters

September Newsletter 2014

Mass. Capital Announces Addition to Investment Team

January 2014 Newsletter

December 2013 Newsletter

October 2013 Newsletter

June 2013 Newsletter

March 2013 Newsletter

Mass. Capital Announces Leadership Transition


Archives